Brandon Capital

AdvanCell is a clinical-stage radiopharmaceutical company focused on developing innovative cancer therapies. The company specializes in alpha-emitting isotopes, specifically 212Pb, which are attached to molecules that target tumors directly. This approach allows for the delivery of cytotoxic radiation at the molecular level, addressing significant challenges in targeted alpha therapy regarding supply reliability and scalability. By providing safe and effective treatments for various forms of cancer, AdvanCell aims to establish its therapies as a standard of care in oncology.

CatalYm GmbH, founded in 2016 and based in Munich, Germany, is a biotechnology company focused on developing innovative immunotherapies for cancer patients. The company has identified GDF-15 as a key regulator of the immune system within the tumor microenvironment. By neutralizing GDF-15, CatalYm aims to enhance the immune response against solid tumors, potentially leading to meaningful clinical outcomes. Its CTL-002 program is designed to demonstrate clinical proof-of-concept across multiple solid tumor indications, offering the prospect of expanding treatment options for cancer patients. Through its approach, CatalYm seeks to transform the tumor microenvironment, making tumors more accessible to the immune system and improving both survival rates and quality of life for patients.

Pheon Therapeutics is a London-based company established in 2022, specializing in the development of Antibody-Drug Conjugates (ADCs) aimed at addressing a variety of difficult-to-treat cancers. The company focuses on creating next-generation ADCs, with its lead program targeting a novel antigen that is significantly expressed in solid tumors across multiple hard-to-treat cancer types. By enhancing the therapeutic options available to healthcare providers, Pheon Therapeutics aims to provide effective treatment alternatives for patients whose cancers do not respond to existing therapies.

Currus Biologics is a biotechnology company focused on developing CAR-T cell therapies aimed at treating solid tumors. The company specializes in creating bispecific antigen-presenting and T-cell engagers to target various cancers, including breast, colon, pancreatic, and prostate cancers. By innovating chimeric antigen receptors, Currus Biologics seeks to enhance the efficacy of cancer treatments, enabling patients with solid tumor indications to receive more effective therapies.

PolyActiva specializes in developing proprietary drug-polymer conjugate technology for site-specific drug delivery through various medical device components, including ocular implants and drug-eluting fibers. The company’s delivery platform is designed to carry concentrated drug products while maintaining the ability to deliver therapeutic doses over extended periods, enhancing treatment efficacy. This technology includes biodegradable implants that facilitate sustained drug delivery, ultimately aiming to improve patient outcomes and quality of life for individuals suffering from ophthalmic conditions, such as glaucoma. By enabling healthcare organizations to offer more effective drug treatments, PolyActiva addresses critical needs within the medical field.

Respirion Pharmaceuticals is an early-stage biotechnology company established in 2018 that specializes in developing innovative treatments for respiratory diseases, particularly Cystic Fibrosis. Originating as a spinout from the Telethon Kids Institute in Perth, the company has focused on creating an inhaled therapy that combines the antibiotic tobramycin with an adjuvant designed to disrupt bacterial biofilms in the lungs. This approach aims to enhance the efficacy of antibiotics and improve patient outcomes in combating lung infections associated with Cystic Fibrosis. The company's lead product has demonstrated promising results in initial clinical trials, which were conducted in collaboration with the Western Australian Department of Health. To advance its research and clinical trials further, Respirion has formed partnerships with prominent organizations, including Australia’s Medical Research Commercialisation Fund and the US Cystic Fibrosis Foundation.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, established in 2020. The company focuses on developing synthetic innate immunomodulators aimed at transforming the treatment and prevention of respiratory infections. Ena Respiratory's novel synthetic Toll-like receptor 2 (TLR2) receptor agonists are designed to activate the innate immune system specifically in the respiratory tract. This innovative approach enables targeted delivery to the airways, helping to prevent the dissemination of viral and bacterial infections to the lungs. By enhancing the immune response, Ena Respiratory aims to protect patients with pre-existing lung conditions from severe complications associated with respiratory infections.

Pathios Therapeutics Limited is an early-stage drug discovery company based in Oxford, United Kingdom, founded in 2017. The company is dedicated to developing therapies for autoimmune diseases and cancer, focusing on small molecule inhibitors that target the pH-sensing G protein-coupled receptor GPR65. These inhibitors are designed to mitigate the immunosuppressive polarization of immune cells, such as tumor-associated macrophages, which is often stimulated by the acidic microenvironment present in tumors. By employing a rigorous scientific approach that includes insights from human genetics and advanced cellular immunology, Pathios aims to generate novel therapeutics that can address advanced solid tumors and other significant medical needs in immuno-oncology.

AstronauTx is a biotechnology company focused on developing treatments for Alzheimer's disease and other neurodegenerative conditions. The company aims to restore the normal functioning of astrocytes, which are crucial cells in the brain that support neuronal activity, metabolism, and the integrity of the blood-brain barrier. In conditions such as dementia, astrocytes can become dysfunctional, leading to neurotoxicity and exacerbating disease progression. By targeting astrocyte homeostasis, AstronauTx seeks to enable healthcare professionals to effectively address the underlying mechanisms of neurotoxicity associated with these diseases, ultimately improving treatment options for patients suffering from dementia and related disorders.

Cincera Therapeutics Pty Ltd is a privately held biotechnology company based in Mawson Lakes, Australia, established in 2017. The company specializes in the discovery and development of small molecule drugs aimed at treating challenging inflammatory and fibrotic conditions linked to obesity, metabolic disorders, and cancer. Cincera's innovative approach focuses on creating effective therapies that address difficult-to-treat diseases, including applications for liver problems and other related health issues, ultimately enabling healthcare providers to improve patient outcomes.

MycRx is a drug development company based in Melbourne, Australia, focused on creating innovative treatments for cancer and new antibiotics with unique mechanisms of action. The company utilizes its proprietary hit identification technology to develop small molecule inhibitors targeting cMyc, a protein implicated in over 50% of human cancers. These inhibitors aim to regulate the oncoprotein associated with various types of cancer, including blood, melanoma, pancreatic, lung, breast, cervical, prostate, colon, stomach, bladder, and brain cancers, thereby enhancing patient outcomes. Founded in 2013 by a team with extensive experience in the pharmaceutical and biotech sectors, MycRx collaborates with the Peter MacCallum Cancer Centre and CSIRO to advance its research and development efforts. In 2015, the company secured a $5 million investment from the MRCF and CSIRO to support its initiatives.

Aravax is an early-stage biotechnology company based in Melbourne, Australia, dedicated to developing a safe and effective treatment for peanut allergies. Founded in May 2015 through the acquisition of intellectual property from Alfred Health and Monash University, Aravax employs proprietary technology aimed at resetting the immune system to tolerate peanuts without triggering allergic reactions. The company's innovative approach seeks to eliminate the risk of life-threatening responses to peanuts, allowing patients to undergo treatment and potentially overcome mild symptoms such as itchiness, rash, and gastrointestinal upset.

Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed to create enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins.

CatalYm GmbH, founded in 2016 and based in Munich, Germany, is a biotechnology company focused on developing innovative immunotherapies for cancer patients. The company has identified GDF-15 as a key regulator of the immune system within the tumor microenvironment. By neutralizing GDF-15, CatalYm aims to enhance the immune response against solid tumors, potentially leading to meaningful clinical outcomes. Its CTL-002 program is designed to demonstrate clinical proof-of-concept across multiple solid tumor indications, offering the prospect of expanding treatment options for cancer patients. Through its approach, CatalYm seeks to transform the tumor microenvironment, making tumors more accessible to the immune system and improving both survival rates and quality of life for patients.

NRG Therapeutics is a drug discovery company established in 2018 that specializes in developing therapeutic approaches aimed at restoring mitochondrial function to address neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease, and motor neuron disease. The company focuses on creating novel medicines that preserve mitochondrial function and halt disease progression. With a team experienced in neuroscience drug discovery, NRG Therapeutics is initially concentrating on the discovery and development of brain-penetrant inhibitors of the mitochondrial permeability transition pore specifically for Parkinson’s disease. This strategic focus is intended to empower physicians with effective treatment options for patients suffering from chronic neurodegenerative disorders.

Pheon Therapeutics is a London-based company established in 2022, specializing in the development of Antibody-Drug Conjugates (ADCs) aimed at addressing a variety of difficult-to-treat cancers. The company focuses on creating next-generation ADCs, with its lead program targeting a novel antigen that is significantly expressed in solid tumors across multiple hard-to-treat cancer types. By enhancing the therapeutic options available to healthcare providers, Pheon Therapeutics aims to provide effective treatment alternatives for patients whose cancers do not respond to existing therapies.

George Medicines is a drug manufacturing company that improves the management of non-communicable diseases.

Denteric is focused on developing vaccines to combat periodontal diseases, leveraging research from the University of Melbourne and collaboration with CSL Limited. The company's biotechnology platform targets the virulence factors produced by the bacterium Porphyromonas gingivalis and related species, which are known to cause various dental diseases and their complications. By creating these vaccines, Denteric aims to provide effective treatments for patients suffering from dental issues, improving their overall oral health. The company has secured funding that is distributed in three parts annually from 2019 to 2021, supporting its ongoing research and development efforts.

OncoRes Medical is an early-stage medical device company based in Perth, Western Australia, focused on developing an innovative imaging technology that enhances intraoperative surgical procedures. This technology, which employs a novel combination of optical coherence tomography, aims to improve surgical accuracy and reduce complication rates during breast cancer surgeries by providing real-time information that helps surgeons distinguish between tumor and healthy tissue. In collaboration with leading researchers from the University of Western Australia and the Harry Perkins Institute of Medical Research, as well as breast cancer surgeons within the Western Australian public health system, OncoRes Medical is advancing its patent-protected technology. The company is supported by funding from the Medical Research Commercialisation Fund, with the goal of transforming the standard of care in clinical applications that require detailed assessment of tissue microstructure.

Ankere is striving to develop transformative therapies based on excellent science that will enable people to live long and healthy lives.

Perx Health is a digital care management program focused on enhancing treatment adherence for individuals with chronic conditions, including diabetes and behavioral health issues. The platform is specifically designed for clinically complex patients, employing various motivational techniques to engage users with low health literacy. By providing reminders, education, and monitoring of medication regimens, Perx Health effectively boosts adherence rates to 90% among high-risk members. The program incorporates elements of gamification, allowing users to earn rewards for adhering to their treatment schedules. Health plans utilizing Perx Health experience significant clinical improvements, such as better control of HbA1C and cholesterol levels, as well as substantial cost savings and a return on investment of 6-8 times per member.

Allay Therapeutics is focused on developing innovative pain management solutions aimed at improving post-surgical recovery for patients. The company utilizes a proprietary technology platform that integrates validated non-opioid analgesics with biopolymers to create dissolvable therapeutic products. These products are designed to deliver targeted pain relief at the surgical site over extended periods, significantly longer than conventional pain treatments. Allay's lead investigational product, ATX101, is currently undergoing evaluation in a Phase 2 clinical trial for total knee arthroplasty surgeries. With a team of experienced entrepreneurs, scientists, and clinicians based in the San Francisco Bay Area and Singapore, Allay Therapeutics is dedicated to transforming the approach to pain management and addressing the limitations associated with opioid use.

Currus Biologics is a biotechnology company focused on developing CAR-T cell therapies aimed at treating solid tumors. The company specializes in creating bispecific antigen-presenting and T-cell engagers to target various cancers, including breast, colon, pancreatic, and prostate cancers. By innovating chimeric antigen receptors, Currus Biologics seeks to enhance the efficacy of cancer treatments, enabling patients with solid tumor indications to receive more effective therapies.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, established in 2020. The company focuses on developing synthetic innate immunomodulators aimed at transforming the treatment and prevention of respiratory infections. Ena Respiratory's novel synthetic Toll-like receptor 2 (TLR2) receptor agonists are designed to activate the innate immune system specifically in the respiratory tract. This innovative approach enables targeted delivery to the airways, helping to prevent the dissemination of viral and bacterial infections to the lungs. By enhancing the immune response, Ena Respiratory aims to protect patients with pre-existing lung conditions from severe complications associated with respiratory infections.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, established in 2020. The company focuses on developing synthetic innate immunomodulators aimed at transforming the treatment and prevention of respiratory infections. Ena Respiratory's novel synthetic Toll-like receptor 2 (TLR2) receptor agonists are designed to activate the innate immune system specifically in the respiratory tract. This innovative approach enables targeted delivery to the airways, helping to prevent the dissemination of viral and bacterial infections to the lungs. By enhancing the immune response, Ena Respiratory aims to protect patients with pre-existing lung conditions from severe complications associated with respiratory infections.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a primary cause of dry eye disease (DED). The company's portfolio includes a range of compounds designed to address the underlying causes of MGD and improve health outcomes for individuals suffering from ocular surface diseases, where effective treatment options are limited. Azura utilizes a novel drug delivery platform to enhance the efficacy of its therapies. The company is headquartered in Tel Aviv-Yafo, Israel, with operational presence in Australia and the United States, and is supported by a management team experienced in the development and commercialization of novel ocular treatments.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, established in 2020. The company focuses on developing synthetic innate immunomodulators aimed at transforming the treatment and prevention of respiratory infections. Ena Respiratory's novel synthetic Toll-like receptor 2 (TLR2) receptor agonists are designed to activate the innate immune system specifically in the respiratory tract. This innovative approach enables targeted delivery to the airways, helping to prevent the dissemination of viral and bacterial infections to the lungs. By enhancing the immune response, Ena Respiratory aims to protect patients with pre-existing lung conditions from severe complications associated with respiratory infections.

Cincera Therapeutics Pty Ltd is a privately held biotechnology company based in Mawson Lakes, Australia, established in 2017. The company specializes in the discovery and development of small molecule drugs aimed at treating challenging inflammatory and fibrotic conditions linked to obesity, metabolic disorders, and cancer. Cincera's innovative approach focuses on creating effective therapies that address difficult-to-treat diseases, including applications for liver problems and other related health issues, ultimately enabling healthcare providers to improve patient outcomes.

Glyscend Therapeutics is focused on developing innovative treatments for type 2 diabetes, drawing inspiration from the metabolic benefits observed in bariatric surgery. The company has created a non-invasive, orally ingestible intestinal coating designed to replicate the effects of surgery by preventing stimulation of the duodenal mucosa and inhibiting crucial neurohormonal pathways in the proximal gut. This novel approach aims to provide patients with effective glucose control while minimizing side effects such as weight gain and hypoglycemia. Glyscend also seeks to equip endocrinologists and primary care physicians with advanced tools to treat diabetes more effectively, rather than merely managing the condition. Founded in 2014 by Ashish Nimgaonkar, Michael Parlato, and Pratik Patel, Glyscend is committed to enhancing the care pathway for individuals living with type 2 diabetes.

George Medicines is a drug manufacturing company that improves the management of non-communicable diseases.

Pathios Therapeutics Limited is an early-stage drug discovery company based in Oxford, United Kingdom, founded in 2017. The company is dedicated to developing therapies for autoimmune diseases and cancer, focusing on small molecule inhibitors that target the pH-sensing G protein-coupled receptor GPR65. These inhibitors are designed to mitigate the immunosuppressive polarization of immune cells, such as tumor-associated macrophages, which is often stimulated by the acidic microenvironment present in tumors. By employing a rigorous scientific approach that includes insights from human genetics and advanced cellular immunology, Pathios aims to generate novel therapeutics that can address advanced solid tumors and other significant medical needs in immuno-oncology.

Denteric is focused on developing vaccines to combat periodontal diseases, leveraging research from the University of Melbourne and collaboration with CSL Limited. The company's biotechnology platform targets the virulence factors produced by the bacterium Porphyromonas gingivalis and related species, which are known to cause various dental diseases and their complications. By creating these vaccines, Denteric aims to provide effective treatments for patients suffering from dental issues, improving their overall oral health. The company has secured funding that is distributed in three parts annually from 2019 to 2021, supporting its ongoing research and development efforts.

EBR Systems, Inc. is focused on developing innovative implantable devices for cardiac rhythm management, specifically aimed at treating patients with heart failure and cardiac arrhythmias. The company's flagship product, the Wireless Cardiac Stimulation of the Left Ventricle System, utilizes proprietary wireless technology to provide endocardial pacing for cardiac resynchronization therapy. This approach enhances the heart's pumping efficiency by synchronizing the contractions of the left and right ventricles. Founded in 2003 and headquartered in Sunnyvale, California, EBR Systems is committed to advancing therapeutic options for patients suffering from cardiac rhythm diseases through its novel technologies.

Allay Therapeutics is focused on developing innovative pain management solutions aimed at improving post-surgical recovery for patients. The company utilizes a proprietary technology platform that integrates validated non-opioid analgesics with biopolymers to create dissolvable therapeutic products. These products are designed to deliver targeted pain relief at the surgical site over extended periods, significantly longer than conventional pain treatments. Allay's lead investigational product, ATX101, is currently undergoing evaluation in a Phase 2 clinical trial for total knee arthroplasty surgeries. With a team of experienced entrepreneurs, scientists, and clinicians based in the San Francisco Bay Area and Singapore, Allay Therapeutics is dedicated to transforming the approach to pain management and addressing the limitations associated with opioid use.

Q-Sera Pty Ltd specializes in developing innovative blood collection tubes that enhance the efficiency of blood clotting, utilizing snake venom-derived proteins. This technology accelerates the clotting process, allowing for the rapid production of high-quality serum essential for biochemical analysis and clinical diagnostics. The company's approach leverages potent prothrombin activators isolated from the venom of certain snakes, including the Australian Taipan. These proteins are manufactured through modified cell lines using standard pharmaceutical processes, ensuring reliability and effectiveness. By improving the speed and quality of serum production, Q-Sera's technology aims to optimize laboratory efficiency and enhance patient care.

Certa Therapeutics Pty Ltd, a biotechnology company, develops and offers precision medicine to treat patients with kidney diseases. The company uses genetic analysis to identify the patients that will develop kidney fibrosis, the precursor to end-stage kidney failure, and respond to pre-emptive treatment. Its drugs block a receptor that is a key driver of fibrosis (scarring) of the kidney which leads to kidney failure and ultimately dialysis or kidney transplantation. The company was incorporated in 2017 and is based in Melbourne, Australia.

Global Kinetics Corporation Limited, founded in 2007 and based in Melbourne, Australia, specializes in mobile health technology aimed at managing patients with Parkinson's disease and other movement disorders. The company focuses on developing innovative solutions for the monitoring and quantification of movement symptoms associated with neurological diseases. Its primary product, the PKG Data Logger, is a wrist-worn device that automatically records movement data, providing valuable insights to healthcare professionals for diagnosing and treating movement disorders. The technology was developed by a team including Professor Malcolm Horne and Dr. Rob Griffiths from the Florey Institute of Neuroscience & Mental Health, the largest neuroscience research group in Australia.

Okogen, Inc. is a biotechnology company based in Encinitas, California, focused on developing therapeutics for ocular infections affecting both adults and children. The company aims to address unmet needs in the treatment of infectious ocular diseases, particularly where current therapies are inadequate or unavailable. Its lead candidate, OKG-0301, is a potent antiviral that targets viral replication intracellularly, specifically designed to combat adenoviral infections of the eye and other ocular viruses such as herpes simplex virus, varicella-zoster virus, and picornavirus. Through its innovative platform, Okogen strives to reduce patient suffering, enhance quality of life, and preserve vision for those affected by these conditions. Founded in 2015, the company is dedicated to advancing ocular health through its specialized research and development efforts.

Cincera Therapeutics Pty Ltd is a privately held biotechnology company based in Mawson Lakes, Australia, established in 2017. The company specializes in the discovery and development of small molecule drugs aimed at treating challenging inflammatory and fibrotic conditions linked to obesity, metabolic disorders, and cancer. Cincera's innovative approach focuses on creating effective therapies that address difficult-to-treat diseases, including applications for liver problems and other related health issues, ultimately enabling healthcare providers to improve patient outcomes.

George Medicines is a drug manufacturing company that improves the management of non-communicable diseases.

EBR Systems, Inc. is focused on developing innovative implantable devices for cardiac rhythm management, specifically aimed at treating patients with heart failure and cardiac arrhythmias. The company's flagship product, the Wireless Cardiac Stimulation of the Left Ventricle System, utilizes proprietary wireless technology to provide endocardial pacing for cardiac resynchronization therapy. This approach enhances the heart's pumping efficiency by synchronizing the contractions of the left and right ventricles. Founded in 2003 and headquartered in Sunnyvale, California, EBR Systems is committed to advancing therapeutic options for patients suffering from cardiac rhythm diseases through its novel technologies.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a primary cause of dry eye disease (DED). The company's portfolio includes a range of compounds designed to address the underlying causes of MGD and improve health outcomes for individuals suffering from ocular surface diseases, where effective treatment options are limited. Azura utilizes a novel drug delivery platform to enhance the efficacy of its therapies. The company is headquartered in Tel Aviv-Yafo, Israel, with operational presence in Australia and the United States, and is supported by a management team experienced in the development and commercialization of novel ocular treatments.

QUE Oncology, Inc. is a biotechnology company based in Atlanta, Georgia, founded in 2013 through a collaboration between Emory University and The University of Queensland's research commercialization company, UniQuest. The company focuses on developing innovative drug therapies for cancer, particularly breast and prostate cancer, by licensing intellectual property from both institutions. QUE's leading drug candidate, Q-122, is currently in Phase 1b clinical development and targets hot flashes in women undergoing anti-estrogen therapy for breast cancer. This compound is a non-hormonal, orally bioavailable small molecule designed to alleviate moderate to severe vasomotor symptoms, including night sweats. QUE Oncology's research pipeline also encompasses projects related to prostate cancer, melanoma, and cancer pain, aiming to meet significant unmet medical needs in oncology.

Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, established in 2020. The company focuses on developing synthetic innate immunomodulators aimed at transforming the treatment and prevention of respiratory infections. Ena Respiratory's novel synthetic Toll-like receptor 2 (TLR2) receptor agonists are designed to activate the innate immune system specifically in the respiratory tract. This innovative approach enables targeted delivery to the airways, helping to prevent the dissemination of viral and bacterial infections to the lungs. By enhancing the immune response, Ena Respiratory aims to protect patients with pre-existing lung conditions from severe complications associated with respiratory infections.

Elastagen is a clinical stage medical company focused on developing products derived from the human protein tropoelastin, which is essential for the elasticity and resilience of various tissues in the body, including skin and blood vessels. The company has created a synthetic version of elastin that mimics the natural protein found in humans. Its advanced product pipeline targets applications in skin rejuvenation, scar remodeling, and tissue repair. With injectable synthetic human elastin and chemically cross-linked tropoelastin for aesthetic uses, Elastagen aims to help patients maintain skin elasticity and suppleness. Founded after acquiring intellectual property rights to elastin technology developed by Professor Weiss at the University of Sydney, Elastagen has successfully secured funding from prominent life science venture capital firms and expanded its operations to include production in Europe and clinical activities in the UK.

MetaBloQ is a biotechnology company dedicated to the development of innovative drugs aimed at treating various types of cancer, including triple-negative breast cancer, prostate cancer, and melanoma. The company's focus is on creating therapies that effectively block specific metabolic processes in cancer cells while minimizing toxicity to healthy, non-cancerous cells. This approach seeks to provide patients with safer and more tolerable treatment options, enhancing the overall efficacy of cancer care.

Cardiora is a clinical stage biopharmaceutical company established in 2015, dedicated to developing innovative treatments for patients suffering from end-stage heart failure, a condition marked by high mortality rates and frequent hospital admissions. The company's lead program, which is currently in Phase Ib trials, focuses on an oral drug designed to prevent heart failure. This compound aims to improve functional outcomes and safety, thereby enhancing patients' quality of life and reducing the likelihood of hospital readmissions. Cardiora is in the process of completing IND enabling trials and plans to initiate Phase II trials.

Aravax is an early-stage biotechnology company based in Melbourne, Australia, dedicated to developing a safe and effective treatment for peanut allergies. Founded in May 2015 through the acquisition of intellectual property from Alfred Health and Monash University, Aravax employs proprietary technology aimed at resetting the immune system to tolerate peanuts without triggering allergic reactions. The company's innovative approach seeks to eliminate the risk of life-threatening responses to peanuts, allowing patients to undergo treatment and potentially overcome mild symptoms such as itchiness, rash, and gastrointestinal upset.

Global Kinetics Corporation Limited, founded in 2007 and based in Melbourne, Australia, specializes in mobile health technology aimed at managing patients with Parkinson's disease and other movement disorders. The company focuses on developing innovative solutions for the monitoring and quantification of movement symptoms associated with neurological diseases. Its primary product, the PKG Data Logger, is a wrist-worn device that automatically records movement data, providing valuable insights to healthcare professionals for diagnosing and treating movement disorders. The technology was developed by a team including Professor Malcolm Horne and Dr. Rob Griffiths from the Florey Institute of Neuroscience & Mental Health, the largest neuroscience research group in Australia.

OccuRx is a Melbourne-based biopharmaceutical company founded in 2014, focusing on the development of innovative therapeutic strategies for ophthalmic disorders linked to retinal fibrosis. The company aims to address the unmet clinical need for targeted ocular therapies through its proprietary small-molecule drugs, which are designed to enhance visual acuity and prevent vision loss in inflammatory and degenerative eye diseases. OccuRx's strategies enable healthcare professionals to prevent the growth of new and abnormal blood vessels and reduce inflammation in the retina, thereby improving patient outcomes in the treatment of these conditions.

Solvanix is a biotechnology company focused on enhancing the stability and reducing the aggregation of fully human antibodies. Traditional monoclonal antibodies and their fragments often face challenges related to stability and aggregation, which can negatively affect their manufacturability and overall product quality. Solvanix has developed a proprietary technology called StAbilize™ that addresses these issues by improving the stability of monoclonal antibodies, antibody fragments, and bi-specifics. The company collaborates with biotechnology and pharmaceutical partners to optimize their therapeutic antibodies and licenses its StAbilize™ technology to facilitate these improvements.

MycRx is a drug development company based in Melbourne, Australia, focused on creating innovative treatments for cancer and new antibiotics with unique mechanisms of action. The company utilizes its proprietary hit identification technology to develop small molecule inhibitors targeting cMyc, a protein implicated in over 50% of human cancers. These inhibitors aim to regulate the oncoprotein associated with various types of cancer, including blood, melanoma, pancreatic, lung, breast, cervical, prostate, colon, stomach, bladder, and brain cancers, thereby enhancing patient outcomes. Founded in 2013 by a team with extensive experience in the pharmaceutical and biotech sectors, MycRx collaborates with the Peter MacCallum Cancer Centre and CSIRO to advance its research and development efforts. In 2015, the company secured a $5 million investment from the MRCF and CSIRO to support its initiatives.

Heart Metabolics Limited is focused on developing a pharmaceutical therapy for hypertrophic cardiomyopathy (HCM), a condition characterized by the thickening of the heart muscle, which can lead to heart failure and sudden death. With over 100,000 cases in the United States, HCM often presents more severely in younger individuals, particularly athletes. While existing cardiovascular drugs offer some relief, many patients do not benefit from current treatments. Heart Metabolics is advancing perhexiline, a drug already approved in Australia and New Zealand for angina, as a potential therapy for all forms of HCM. Following encouraging results from phase II clinical trials, the company is preparing to conduct further clinical trials in the U.S. and aims to obtain FDA approval for perhexiline as an orphan drug, a designation it already holds. Through this development, Heart Metabolics seeks to address significant unmet medical needs in HCM treatment.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.

Protego Medical is a medical technology company focused on developing a device aimed at providing sternal protection during cardiac surgery. The device addresses challenges associated with sternal bleeding and trauma that can occur during median sternotomy procedures. By enhancing surgical visibility and improving patient outcomes, Protego Medical's innovation offers potential clinical benefits for patients undergoing cardiac interventions, as well as financial savings for hospitals.

Auspherix Pty Ltd. is an early-stage anti-infectives company based in Stevenage, United Kingdom, focused on the discovery and development of organogold-based antibiotics aimed at treating serious and challenging infections that may be life-threatening. Established in 2013, the company is working to advance its novel antibiotic candidates through pre-clinical and clinical development stages. To facilitate this progress, Auspherix is seeking additional investment and industry partnerships to support the broad-spectrum application of its innovative therapies.

PolyActiva specializes in developing proprietary drug-polymer conjugate technology for site-specific drug delivery through various medical device components, including ocular implants and drug-eluting fibers. The company’s delivery platform is designed to carry concentrated drug products while maintaining the ability to deliver therapeutic doses over extended periods, enhancing treatment efficacy. This technology includes biodegradable implants that facilitate sustained drug delivery, ultimately aiming to improve patient outcomes and quality of life for individuals suffering from ophthalmic conditions, such as glaucoma. By enabling healthcare organizations to offer more effective drug treatments, PolyActiva addresses critical needs within the medical field.

G I Therapies is a Melbourne-based company founded in 2012 that specializes in developing non-invasive medical devices aimed at treating gastrointestinal motility disorders. The company's primary focus is on chronic constipation, a condition affecting both adults and children, as well as related issues such as irritable bowel syndrome with constipation and gastroparesis. By commercializing innovative technologies, G I Therapies seeks to enhance the quality of life for patients suffering from these disorders, providing effective solutions that promote better gastrointestinal health.

Q-Sera Pty Ltd specializes in developing innovative blood collection tubes that enhance the efficiency of blood clotting, utilizing snake venom-derived proteins. This technology accelerates the clotting process, allowing for the rapid production of high-quality serum essential for biochemical analysis and clinical diagnostics. The company's approach leverages potent prothrombin activators isolated from the venom of certain snakes, including the Australian Taipan. These proteins are manufactured through modified cell lines using standard pharmaceutical processes, ensuring reliability and effectiveness. By improving the speed and quality of serum production, Q-Sera's technology aims to optimize laboratory efficiency and enhance patient care.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.

Vaxxas is a biotechnology company based in Brisbane, Australia, that specializes in developing a needle-free vaccination technology aimed at transforming vaccine delivery. The company's innovative system employs an array of vaccine-coated micro projections that penetrate the outer layers of the skin when applied with a specialized applicator device. This approach allows for direct deposition of vaccines among a dense concentration of immune cells in the skin. Additionally, Vaxxas utilizes proprietary dry-coating technology to minimize or eliminate the need for refrigeration during the storage and transport of vaccines, thereby alleviating the logistical challenges associated with maintaining the cold chain. Founded in 2011, Vaxxas aims to enhance global vaccination efforts through its novel delivery system.

Signostics Limited is a medical technology company based in Clovelly Park, Australia, that specializes in the development and manufacture of portable point-of-care devices for both medical and veterinary markets. The company's flagship products include the SignosRT Bladder Scanner, which utilizes ultrasound technology to detect the bladder and calculate its volume, and the SignosRT Handheld Ultrasound, designed to assist clinicians in their examinations. These devices cater to a variety of applications, including hospital medicine, family practice, remote healthcare, and physical therapy. Established in 2005, Signostics has expanded its reach internationally, with regulatory approvals for its products in the United States, Europe, and Australia. The company also maintains offices in Palo Alto, California, and continues to focus on delivering innovative and accessible medical solutions through a network of global distributors.

Signostics Limited is a medical technology company based in Clovelly Park, Australia, that specializes in the development and manufacture of portable point-of-care devices for both medical and veterinary markets. The company's flagship products include the SignosRT Bladder Scanner, which utilizes ultrasound technology to detect the bladder and calculate its volume, and the SignosRT Handheld Ultrasound, designed to assist clinicians in their examinations. These devices cater to a variety of applications, including hospital medicine, family practice, remote healthcare, and physical therapy. Established in 2005, Signostics has expanded its reach internationally, with regulatory approvals for its products in the United States, Europe, and Australia. The company also maintains offices in Palo Alto, California, and continues to focus on delivering innovative and accessible medical solutions through a network of global distributors.

Fibrotech Therapeutics focuses on developing innovative drug candidates aimed at treating fibrosis related to various chronic conditions. The company's research and development efforts are directed towards addressing diseases such as diabetic nephropathy, kidney diseases, heart failure, pulmonary fibrosis, and arthritis. Founded in 2006 and based in Wonga Park, Australia, Fibrotech Therapeutics is dedicated to improving patient outcomes through its targeted therapeutic solutions.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.